BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36105405)

  • 41. Identification of novel lipid metabolic biomarkers associated with poor adrenocortical carcinoma prognosis using integrated bioinformatics.
    Subramanian C; Cohen MS
    Surgery; 2022 Jan; 171(1):119-129. PubMed ID: 34353633
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Li S; Wu X; Pei Y; Wang W; Zheng K; Qiu E; Zhang X
    DNA Cell Biol; 2019 Nov; 38(11):1323-1337. PubMed ID: 31536386
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The relationship between the expression of Ki-67 and the prognosis of osteosarcoma.
    Zeng M; Zhou J; Wen L; Zhu Y; Luo Y; Wang W
    BMC Cancer; 2021 Mar; 21(1):210. PubMed ID: 33648449
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The canonical Wnt-beta-catenin pathway in development and chemotherapy of osteosarcoma.
    Li C; Shi X; Zhou G; Liu X; Wu S; Zhao J
    Front Biosci (Landmark Ed); 2013 Jun; 18(4):1384-91. PubMed ID: 23747891
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Wnt signaling in osteosarcoma.
    Lin CH; Ji T; Chen CF; Hoang BH
    Adv Exp Med Biol; 2014; 804():33-45. PubMed ID: 24924167
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/β-catenin signaling through stabilization of the WNT-receptor complex.
    Zhao SJ; Jiang YQ; Xu NW; Li Q; Zhang Q; Wang SY; Li J; Wang YH; Zhang YL; Jiang SH; Wang YJ; Huang YJ; Zhang XX; Tian GA; Zhang CC; Lv YY; Dai M; Liu F; Zhang R; Zhou D; Zhang ZG
    Oncogene; 2018 Feb; 37(8):1049-1061. PubMed ID: 29084211
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Abnormal DNA methylation may contribute to the progression of osteosarcoma.
    Chen XG; Ma L; Xu JX
    Mol Med Rep; 2018 Jan; 17(1):193-199. PubMed ID: 29115427
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of molecular marker associated with ovarian cancer prognosis using bioinformatics analysis and experiments.
    Zheng MJ; Li X; Hu YX; Dong H; Gou R; Nie X; Liu Q; Ying-Ying H; Liu JJ; Lin B
    J Cell Physiol; 2019 Jul; 234(7):11023-11036. PubMed ID: 30633343
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IL-17A/IL-17RA interaction promoted metastasis of osteosarcoma cells.
    Wang M; Wang L; Ren T; Xu L; Wen Z
    Cancer Biol Ther; 2013 Feb; 14(2):155-63. PubMed ID: 23192273
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Potential Regulatory Effects of miR-182-3p in Osteosarcoma via Targeting EBF2.
    Chen G; Yu W; Li Z; Wang Q; Yang Q; Du Z; Zhang G; Song Y
    Biomed Res Int; 2019; 2019():4897905. PubMed ID: 30993113
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma.
    Yang H; Zhao L; Zhang Y; Li FF
    Cancer Med; 2021 Aug; 10(16):5696-5711. PubMed ID: 34258887
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Down-regulation of microRNA-31-5p inhibits proliferation and invasion of osteosarcoma cells through Wnt/β-catenin signaling pathway by enhancing AXIN1.
    Chen X; Zhong L; Li X; Liu W; Zhao Y; Li J
    Exp Mol Pathol; 2019 Jun; 108():32-41. PubMed ID: 30844369
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CircECE1 activates energy metabolism in osteosarcoma by stabilizing c-Myc.
    Shen S; Yao T; Xu Y; Zhang D; Fan S; Ma J
    Mol Cancer; 2020 Oct; 19(1):151. PubMed ID: 33106166
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MCAM is associated with metastasis and poor prognosis in osteosarcoma by modulating tumor cell migration.
    Du X; Zhang Q; Wang S; Chen X; Wang Y
    J Clin Lab Anal; 2022 Feb; 36(2):e24214. PubMed ID: 34961985
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Downregulation of the Proton-Activated Cl- Channel TMEM206 Inhibits Malignant Properties of Human Osteosarcoma Cells.
    Peng F; Li H; Li J; Wang Z
    Oxid Med Cell Longev; 2021; 2021():3672112. PubMed ID: 34777684
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Bioinformatics analysis of differently expressed genes in osteoblastic sarcoma and screening of key genes].
    Shen RK; Huang Z; Zhu X; Lin JH
    Zhonghua Zhong Liu Za Zhi; 2022 Feb; 44(2):147-154. PubMed ID: 35184458
    [No Abstract]   [Full Text] [Related]  

  • 57. Serglycin promotes proliferation, migration, and invasion via the JAK/STAT signaling pathway in osteosarcoma.
    Lv B; Gao G; Guo Y; Zhang Z; Liu R; Dai Z; Ju C; Liang Y; Tang X; Tang M; Lv XB
    Aging (Albany NY); 2021 Sep; 13(17):21142-21154. PubMed ID: 34493692
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MiR-199b-5p promotes malignant progression of osteosarcoma by regulating HER2.
    Chen Z; Zhao G; Zhang Y; Ma Y; Ding Y; Xu N
    J BUON; 2018; 23(6):1816-1824. PubMed ID: 30610808
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Silencing of RIPK4 inhibits epithelial‑mesenchymal transition by inactivating the Wnt/β‑catenin signaling pathway in osteosarcoma.
    Yi Z; Pu Y; Gou R; Chen Y; Ren X; Liu W; Dong P
    Mol Med Rep; 2020 Mar; 21(3):1154-1162. PubMed ID: 32016450
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MYLK4 promotes tumor progression through the activation of epidermal growth factor receptor signaling in osteosarcoma.
    Yang M; Zhang T; Zhang Y; Ma X; Han J; Zeng K; Jiang Y; Wang Z; Wang Z; Xu J; Hua Y; Cai Z; Sun W
    J Exp Clin Cancer Res; 2021 May; 40(1):166. PubMed ID: 33980265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.